Sirolimus pros and cons: what the evidence actually shows

Last updated 2026-07-30

What is sirolimus and why do longevity researchers care about it?

Sirolimus is the generic name for the drug also known as rapamycin. They are the same molecule; sirolimus is the INN (International Nonproprietary Name) and rapamycin is the original name given after its discovery in a soil sample from Easter Island (Rapa Nui) in the 1970s ^[1]. You'll see both names used interchangeably in papers and on forums, and that's not a marketing trick, it's just naming history. The FDA approved sirolimus in 1999 as an immunosuppressant to prevent organ rejection after kidney transplant, sold under the brand name Rapamune ^[2]. Since then it's picked up other approved uses: Fyarro (albumin-bound sirolimus) for a rare soft tissue cancer called malignant perivascular epithelioid cell tumor, and Hyftor, a topical formulation for skin lesions in tuberous sclerosis complex ^[3]. None of these approvals have anything to do with lifespan or aging. The longevity interest comes from a different place: mechanistic biology. Sirolimus inhibits a protein complex called mTOR (mechanistic target of rapamycin), which sits at the center of how cells decide to grow, divide, or conserve resources. Dialing down mTOR activity mimics some of the cellular effects of caloric restriction, which is the most consistently reproduced life-extension intervention in animal biology. That mechanistic story, combined with genuinely strong mouse data, is why sirolimus is one of the most discussed off-label longevity drugs today, alongside metformin and acarbose. It is also why serious researchers keep saying the same thing: the mouse data is real, the human data isn't there yet.

What does the mouse and animal data actually show?

The anchor evidence is the National Institute on Aging's Interventions Testing Program (ITP), a multi-site, genetically diverse mouse study that has tested dozens of compounds since 2004 under a standardized protocol. Sirolimus is the ITP's best-performing compound by a wide margin. In the first ITP cohort, sirolimus fed starting at 600 parts per million in food beginning at 20 months of age extended median lifespan by 9% in males and 14% in females ^[4]. That's already notable because it worked even when started late in life, equivalent to roughly a 60-year-old human starting treatment. Later cohorts starting sirolimus earlier (at 9 months) or at higher doses saw bigger effects: one dose-response study found lifespan extension up to about 26% in males and 21% in females at higher doses, and some individual cohort/dose combinations have shown effects reported in press coverage as high as 60% in specific subgroups ^[5]. The dose-response relationship is real: more sirolimus, more lifespan extension, up to a point where side effects start to bite. The effect isn't limited to one species. Studies in fruit flies, worms (C. elegans), and yeast show lifespan extension from mTOR inhibition, which is part of why researchers consider the pathway itself, more than the drug, to be a genuine aging mechanism rather than a mouse-specific fluke ^[6]. Rapamycin has also shown effects on markers of frailty, cardiac aging, and cognitive decline in rodent studies, more than raw survival curves. Here's the honest caveat: mice are not small humans. Mice have shorter lives, different cancer biology (many strains die of lymphoma, which sirolimus's immunosuppressive and antiproliferative effects may specifically blunt), and live in controlled lab conditions with no infections, no traffic accidents, and standardized diets. A drug that adds 10-25% to a mouse's 2-3 year lifespan is a strong signal, not proof it does the same for an 80-year human lifespan.

Is there any human trial data on sirolimus and lifespan?

No completed trial has tested sirolimus for human lifespan extension, and this is the central gap in the entire longevity conversation around the drug. Nobody can honestly tell you sirolimus adds years to human life, because that trial doesn't exist yet. What does exist is a small but growing set of human studies on surrogate markers, not lifespan itself. A 2014 Novartis-funded trial (using RAD001, an mTOR inhibitor related to sirolimus) found that low-dose mTOR inhibition improved influenza vaccine antibody response in elderly volunteers, suggesting the drug can boost rather than only suppress certain immune functions at low doses ^[7]. A small trial from Joan Mannick and colleagues (PEARL study framework) looked at markers of immune function and skin aging in healthy older adults. These are interesting, hypothesis-generating results. They are not survival data. There is currently no FDA-approved indication for aging, and the FDA does not recognize "aging" as a treatable indication at all, which is part of why no pharmaceutical company has run a registrational trial for longevity: there's no regulatory pathway to sell the drug for that use even if the trial succeeded. Human dosing protocols circulating online (5-6mg once weekly, for example) are extrapolated from transplant pharmacokinetics and animal dose-scaling, not from a dedicated aging trial. If you want a fuller picture of what user-reported experience looks like in absence of trial data, see sirolimus reviews and the sirolimus results timeline, which lay out what people track and when they say they notice changes.

What are the real pros of sirolimus for longevity use?

The strongest pro is the mouse data itself: no other compound tested by the NIA ITP has matched sirolimus's consistency across sites, sexes, and cohorts ^{[4] [5]}. That's not nothing. It's the best animal evidence any longevity-associated drug has. Second, the mechanism is plausible and well-studied. mTOR inhibition mimics caloric restriction's cellular effects (autophagy activation, reduced protein synthesis, reduced growth signaling) without requiring someone to actually eat 30% less food for decades, which is famously hard to sustain in humans. Third, decades of transplant-dose safety data exist. Sirolimus has been prescribed continuously since 1999, so we know a great deal about its side effect profile at immunosuppressive doses, even though longevity users take it differently (typically intermittent, once-weekly, low-dose protocols rather than continuous daily transplant dosing). That's a real advantage over newer, less-studied longevity compounds: we're not flying blind on toxicology. Fourth, some human surrogate-marker data is genuinely encouraging, particularly the vaccine response study showing improved, more than suppressed, immune function at low intermittent doses ^[7]. That result cuts against the simple "it's an immunosuppressant, therefore bad" framing and suggests dose and schedule matter enormously.

What are the real cons and risks of sirolimus?

Immunosuppression is the headline risk, and it's not theoretical. At transplant doses, sirolimus increases infection risk and is associated with impaired wound healing, which is why surgeons often tell patients to stop it before elective procedures ^[2]. Longevity users take much lower, intermittent doses specifically to try to dodge this, but nobody has run the long-term study confirming that low-dose intermittent dosing avoids immune impairment in otherwise healthy people. That's an assumption, not a proven fact. Mouth ulcers (stomatitis) are the most commonly reported side effect in both transplant patients and longevity self-experimenters. In the original transplant trials, rates of mouth ulcers were meaningfully elevated versus placebo, and it remains one of the top complaints in longevity user reports and forums ^{[2] [2]}. Metabolic effects are the other major concern. Sirolimus is associated with elevated LDL cholesterol and triglycerides, and in some patients, new-onset or worsened insulin resistance and hyperglycemia ^{[2] [2]}. This is somewhat paradoxical against the longevity framing, since metabolic dysfunction is itself an aging risk factor, and it's a big part of why researchers argue about optimal dosing schedule (continuous versus intermittent, and what dose) rather than whether the drug works at all. Other documented risks at clinical doses include delayed wound healing, increased risk of certain skin cancers with long-term continuous immunosuppression, lung inflammation (interstitial lung disease, rare but documented), and edema ^[2]. Nearly all of this safety data comes from continuous, higher-dose transplant use, not the once-weekly low-dose protocols longevity users favor, so applying it directly overstates some risks and probably understates our uncertainty about others. | Factor | Evidence quality | What we know |

How does the off-label longevity protocol differ from the FDA-approved use?

FDA-approved sirolimus dosing for transplant patients is continuous and daily, typically starting around 6mg loading dose then 2mg daily, adjusted to trough blood levels around 4-12 ng/mL depending on the transplant protocol and concurrent drugs ^[2]. That's a steady-state immunosuppressive regimen designed to keep a foreign organ from being rejected, which requires sustained immune dampening. The off-label longevity approach almost always uses intermittent dosing, commonly once weekly, at doses ranging roughly from 3mg to 10mg depending on the individual protocol and body weight, with the theory being that a pulsed high dose inhibits mTORC1 (the complex linked to most anti-aging benefit) while giving mTORC2 (linked to some metabolic and immune functions) time to recover between doses ^[8]. This idea comes from researchers like Mikhail Blagosklonny, who proposed intermittent dosing specifically to separate the beneficial mTORC1 inhibition from unwanted mTORC2-related side effects. This is a real, biologically motivated hypothesis. It is also, again, not validated by a completed human trial measuring hard outcomes. It's borrowed logic from receptor biology and short-term human studies, applied to a decades-long question (does this change how long you live) that we simply can't answer yet with the data in hand. Anyone telling you the once-weekly protocol is "proven safe long-term" is overstating the evidence.

Who should not take sirolimus off-label?

Anyone with an active infection, a history of poor wound healing, upcoming surgery, or a compromised immune system for other reasons should be cautious, given sirolimus's documented immunosuppressive and wound-healing effects at approved doses ^[2]. This is true even though longevity dosing is lower than transplant dosing; we don't have data proving the lower dose is fully protective against these same effects. People with significantly elevated LDL cholesterol or triglycerides, or poorly controlled diabetes, should discuss the metabolic risk profile carefully with a prescriber before starting, since sirolimus can worsen both ^{[2] [2]}. Pregnant or breastfeeding people should not take it; animal reproduction studies showed fetal harm and it's not established safe in pregnancy ^[2]. Anyone currently on other immunosuppressants, certain antifungals (like ketoconazole), or strong CYP3A4 inhibitors/inducers needs a prescriber who understands the drug interaction landscape; sirolimus blood levels can swing widely with certain drug combinations ^[2]. This is a drug that genuinely benefits from being managed by someone who can order and interpret blood levels, not something to self-titrate from an online forum protocol without any monitoring at all.

How much does sirolimus cost and how do you get it legally?

Sirolimus requires a prescription in the United States; it is not sold over the counter or as a supplement. Generic oral sirolimus tablets are widely available since the drug lost patent exclusivity years ago, and generic pricing is substantially lower than the original brand-name Rapamune. Actual cash price varies by pharmacy and dose, but generic sirolimus commonly runs in the range of low tens of dollars up to roughly $100+ per month for typical longevity-protocol doses, depending on pharmacy, quantity, and whether insurance (which generally won't cover off-label longevity use) is in play. Because it's off-label for longevity, most insurance plans won't reimburse a prescription written for anti-aging purposes; you're typically paying cash. For a legitimate route, that means finding a prescriber willing to evaluate you for off-label use, order baseline labs (lipid panel, kidney and liver function, complete blood count), and monitor periodically, then working with a licensed pharmacy to fill the prescription. Sirolimus Rx works with a provider-reviewed process that connects patients to a licensed prescriber for evaluation and a fulfilling pharmacy partner for dispensing, rather than compounding or manufacturing anything itself. That structure, physician evaluation plus pharmacy fulfillment plus lab monitoring, is the version of "getting sirolimus" that has any real safety net attached to it, versus buying unregulated product from an overseas research-chemical site.

Does sirolimus interact badly with other longevity drugs like metformin?

There's no strong human data showing a dangerous interaction between sirolimus and metformin specifically, and some researchers have proposed combining mTOR inhibition with metformin's AMPK-activating effects as complementary longevity mechanisms, but this combination hasn't been tested in a dedicated human trial either. Caution and prescriber oversight matter here precisely because the combination is unstudied, not because there's a known specific danger. What is well documented is that sirolimus has real pharmacokinetic interactions with drugs metabolized through CYP3A4, including many antifungals, certain antibiotics, and grapefruit juice, all of which can raise sirolimus blood levels significantly ^[2]. If you're stacking supplements or drugs on top of a sirolimus protocol, that's a conversation for a prescriber who can check for interactions, not a guess based on a forum thread.

Is sirolimus worth trying for longevity right now?

That depends heavily on your risk tolerance and how you weigh strong animal evidence against total absence of human lifespan data. If you want a fuller framework for thinking through that tradeoff, is sirolimus worth it walks through the decision in more depth, and sirolimus success rate covers what "success" even means for people using it off-label given the lack of hard outcome data. My honest take: the mouse data is about as strong as animal longevity evidence gets, and the mechanism is credible science, not hype. But anyone selling you certainty about human lifespan extension is selling you something the data doesn't support. If you go this route, do it through a real prescriber, with baseline and follow-up labs, at conservative doses, with full awareness that you're participating in a large, informal, uncontrolled experiment rather than following an established medical protocol. If you're deciding whether to start, sirolimus first month what to expect and sirolimus before and after are useful for calibrating what people actually report early on, separate from the mouse data question entirely.

Frequently asked questions

Is sirolimus the same as rapamycin?

Yes. Rapamycin is the original name given to the compound discovered in soil from Easter Island in the 1970s. Sirolimus is its International Nonproprietary Name (INN), used on FDA labeling and prescriptions. They refer to the identical molecule; the names are used interchangeably in both scientific literature and longevity communities.

Has sirolimus been proven to extend human lifespan?

No. There is no completed human trial measuring whether sirolimus extends lifespan. The strongest evidence is in mice, via the NIA's Interventions Testing Program, which showed median lifespan increases up to roughly 9-26% or more depending on dose and cohort. Human data is limited to short-term studies of immune and metabolic markers, not survival.

What is the biggest risk of taking sirolimus off-label?

Immunosuppression is the primary documented risk at approved transplant doses, raising infection risk and impairing wound healing. Longevity users take lower, intermittent doses to try to reduce this risk, but there's no long-term human study confirming that low-dose weekly dosing avoids meaningful immune suppression in healthy people.

Does sirolimus cause mouth ulcers?

Yes, stomatitis (mouth ulcers) is one of the most commonly reported side effects, documented in transplant clinical trials and frequently reported by longevity users on intermittent low-dose protocols. It's usually manageable with dose adjustment but is one of the most common reasons people discontinue or reduce dosing.

How does sirolimus affect cholesterol and blood sugar?

Sirolimus is associated with elevated LDL cholesterol and triglycerides, and can worsen insulin resistance or blood sugar control in some patients, based on data from FDA-approved transplant dosing. This is a real consideration since metabolic dysfunction is itself a driver of aging, making baseline and follow-up lab monitoring important for anyone using it off-label.

What dose do longevity users typically take compared to transplant patients?

Transplant patients take sirolimus continuously and daily, typically around 2mg/day after a loading dose, adjusted by blood trough levels. Off-label longevity protocols typically use intermittent dosing, often once weekly at roughly 3-10mg, based on a theory proposed by researchers like Mikhail Blagosklonny to limit side effects, though this schedule hasn't been validated in a dedicated long-term human trial.

Is sirolimus FDA-approved for anti-aging?

No. Sirolimus is FDA-approved for preventing organ transplant rejection (since 1999, as Rapamune), and in specific formulations (Fyarro, Hyftor) for a rare tumor type and tuberous sclerosis-related skin lesions. There is no FDA-approved indication for aging or longevity, and the FDA does not currently recognize aging itself as a treatable condition.

How much does sirolimus cost per month for off-label use?

Generic sirolimus is inexpensive relative to many longevity drugs since it's off-patent; monthly cash cost for typical off-label protocol doses commonly runs from roughly the low tens of dollars up to around $100 or more depending on pharmacy, dose, and quantity. Insurance generally does not cover prescriptions written for off-label longevity use.

Can I buy sirolimus without a prescription?

Not legally in the United States. Sirolimus requires a prescription. Unregulated "research chemical" sources exist online but carry real risks around purity, dosing accuracy, and lack of any medical oversight or lab monitoring. A legitimate path involves a licensed prescriber evaluation and a licensed pharmacy for dispensing.

Does sirolimus interact with metformin or other supplements?

There's no strong evidence of a dangerous interaction between sirolimus and metformin, and some researchers propose combining them for complementary mechanisms, but the combination hasn't been tested in dedicated human trials. Sirolimus does have well-documented pharmacokinetic interactions with CYP3A4-affecting drugs and grapefruit juice, which can raise blood levels significantly.

What did the NIA Interventions Testing Program actually find?

The NIA's ITP, a multi-site study using genetically diverse mice, found sirolimus extended median lifespan by about 9% in males and 14% in females when started at 20 months of age, with larger effects (up to roughly 26%) seen at higher doses or earlier starts in later cohorts. It remains the best-performing compound the ITP has tested.

Who should avoid taking sirolimus off-label?

People with active infections, upcoming surgery, poor wound healing history, significantly elevated cholesterol or triglycerides, poorly controlled diabetes, or who are pregnant or breastfeeding should avoid it or discuss it carefully with a prescriber first, given documented immunosuppressive, metabolic, and wound-healing risks at approved doses.

Sources

1. NIH National Center for Biotechnology Information, PubChem - Sirolimus: Sirolimus was discovered in a soil sample from Easter Island (Rapa Nui) and is also known as rapamycin
2. FDA - Rapamune (sirolimus) Prescribing Information: FDA-approved dosing, indications, and warnings for sirolimus (Rapamune) in transplant patients, approved 1999
3. FDA - Fyarro Approval: FDA approved Fyarro (sirolimus protein-bound particles) for malignant PEComa
4. Harrison DE et al., Nature - NIA Interventions Testing Program: NIA Interventions Testing Program findings that sirolimus extended median lifespan in genetically heterogeneous mice starting at 20 months of age
5. Miller RA et al., Journals of Gerontology - Rapamycin dose-response in mice: Higher-dose and earlier-start sirolimus produced larger lifespan extension in later ITP cohorts
6. Johnson SC, Rabinovitch PS, Kaeberlein M, Nature - mTOR is a key modulator of ageing: mTOR inhibition extends lifespan across yeast, worms, flies, and mice, supporting the pathway as a conserved aging mechanism
7. Mannick JB et al., Science Translational Medicine - mTOR inhibition improves immune function in the elderly: Low-dose mTOR inhibitor improved influenza vaccine antibody response in elderly volunteers in a randomized trial
8. Blagosklonny MV, Aging (Albany NY) - Fasting and rapamycin: Rationale for intermittent dosing of rapamycin to separate mTORC1 inhibition benefits from mTORC2-related side effects